ESTRO 2024 - Abstract Book

S1067

Clinical - Gynaecology

ESTRO 2024

With ERT, treatment with 3D technique was used in 8 patients (23.5%), 2 patients (5.9%) with 2D, 2 patients (5.9%) IMRT, 1 patient (2.9%) with VMAT.

The equipment used for brachytherapy treatment in recurrences: 12 patients (35.3%) treated with cylinder, 8 patients with colpostates and 1 patient (2.9%) with simultaneous equipment.

The most frequently used scheme, as a re-irradiation dose with ERT, was 30 Gy in 10 fx. The median dose with high-rate brachytherapy was 30Gy in 5 applications of 6 Gy.

In toxicity, 1 patient (2.9%) with G2 proctitis, 1 patient (2.9%) with G3 proctitis and 1 patient (2.9%) with G2 cystitis was observed.

Complete response rates were found to be between 33% and 70% among the various treatment modalities.

The survival time after re-irradiation for recurrence was a median of 19 months.

Table 1 details the characteristics of the primary tumor and the initial treatment, as well as the time of reirradiation and its response.

Conclusion:

Recurrence due to cervical cancer on a previously irradiated site can be managed with various technical modalities according to various factors, which provide individualization of the patient. According to the results of our series, in terms of response and toxicity profile, we can propose this management in those patients who, due to the context of unresectability, inoperability, or due to distant disease, in addition to locoregional recurrence/persistence, cannot be taken to pelvic exenteration.